About Us



Page 11234..10..»




Radient Technologies Announces partnership with US based Dreamy CBD

Posted: November 26, 2020 at 1:56 am


EDMONTON, Alberta, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), is pleased to announce a licensing agreement with Dreamy Co., (“Dreamy”) to bring in Dreamy CBD products under Radient’s platform to Canada and extend it to other international markets. Initially founded in the US, Dreamy has developed a lifestyle brand over the past decade focused on the Health and Wellness space before branching into the CBD vertical. Dreamy is focused on creating and inspiring people to use plant medicine and holistic healing in place of conventional pharmaceutical solutions. In the US, Dreamy CBD enjoys a strong presence in California, and the Dreamy brand has a strong association with a positive lifestyle in the rapidly growing Wellness space. The Dreamy CBD products comprise CBD tinctures, CBD distillates, CBD edibles, CBD cosmetics, and CBD Vape Cartridges geared towards the recreational and medical cannabis market.

Follow this link:
Radient Technologies Announces partnership with US based Dreamy CBD

AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

Posted: at 1:56 am


SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. With a strong fourth quarter already underway, the Company forecasts a revenue growth of approximately 100% in 2020 over 2019, with a revenue range of US$3 million (~ RMB20 million) to US$3.3 million (~ RMB22 million). For 2019, the Company had a revenue of US$1.6 million (~ RMB10.9 million) (using a current US$ to RMB exchange ratio of ~ 6.6). We expect the strong momentum of YoY revenue growth due to market demand and customers accepting AnPac Bio’s novel cancer screening technology with multiple advantages (named cancer differentiation analysis (CDA) technology)) to continue into 2021. The Company plans to release its full year 2020 audited financial report in early March 2021.

Go here to see the original:
AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

Posted: at 1:56 am


MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd today announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) technology to develop novel immunotherapies for a range of cancers and infectious diseases.

View original post here:
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit…

Posted: at 1:56 am


Read more:
Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit...

Equillium Provides Itolizumab COVID-19 Program Update

Posted: at 1:56 am


Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020

Here is the original post:
Equillium Provides Itolizumab COVID-19 Program Update

Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Posted: at 1:56 am


FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.

Visit link:
Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders

Posted: at 1:56 am


WOBURN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders. The advisors join as the Company continues development of its neutralizing antibody therapeutic, ABP300, in clinical trials for treatment of SARS-CoV2 (COVID-19) infection.

See the article here:
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders

GBT Announces Participation in Upcoming Investor Conferences

Posted: at 1:56 am


SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:

View post:
GBT Announces Participation in Upcoming Investor Conferences

Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) – 3 years ISO 9001-2015 certification successfully obtained

Posted: at 1:56 am


Loos, France, Isovital Headquarter, Nov 24th 2020 - Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) - 3 years ISO 9001-2015 certification successfully obtained for the “National, international distribution and logistics of cooled pharmaceutical, biological, diagnostic and radioactive products”.

See the original post:
Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) - 3 years ISO 9001-2015 certification successfully obtained

VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference

Posted: at 1:56 am


BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.

Read the original:
VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference

Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Posted: at 1:56 am


CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president, and Elizabeth Trehu, M.D., chief medical officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

The rest is here:
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

AgraFlora Organics Receives Analytical Equipment for its Winnipeg Edibles Manufacturing Facility

Posted: at 1:56 am


VANCOUVER, British Columbia, Nov. 25, 2020 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc.  (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that it has acquired High Performance Liquid Chromatography (“HPLC”) equipment for AgraFlora’s 51,000-Square-foot fully-automated edibles manufacturing facility in Winnipeg, Manitoba (the “Edibles Facility”).

See the article here:
AgraFlora Organics Receives Analytical Equipment for its Winnipeg Edibles Manufacturing Facility

Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Posted: at 1:56 am


PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 and host investor meetings.

Continued here:
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Posted: at 1:56 am


WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020. Aquestive will host one-on-one investor meetings on December 2, 2020.

Here is the original post:
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

Posted: at 1:56 am


Company announcement no. 29/2020

See original here:
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

Posted: at 1:56 am


LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.

See the original post here:
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

Posted: at 1:56 am


TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

Read more:
Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

Novavax to Participate in Upcoming Conferences

Posted: at 1:56 am


GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.

Link:
Novavax to Participate in Upcoming Conferences

Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

Posted: at 1:56 am


AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

Here is the original post:
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

Posted: at 1:56 am


NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval regulation based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered to patients three times in a week in an outpatient setting and the treatment is repeated every four weeks. The product has received Priority Review, Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations from the FDA.

Read more:
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

Next Posts »



Page 11234..10..»